Source comparison
Side-by-Side Comparison
Mechanism VEGF, EGF, FGF upregulation; NO modulation; growth factor pathways Actin polymerization regulation; cell migration; anti-inflammatory Evidence Grade A B+ Source Gastric juice-derived pentadecapeptide (15 AA) Synthetic fragment of Thymosin Beta-4 (43
This comparison does not assign a generated winner or score.
- Mechanism
- VEGF, EGF, FGF upregulation; NO modulation; growth factor pathways
- Actin polymerization regulation; cell migration; anti-inflammatory
- Evidence Grade
- A
- B+
- Source
- Gastric juice-derived pentadecapeptide (15 AA)
- Synthetic fragment of Thymosin Beta-4 (43 AA)
- Route
- Subcutaneous (local or systemic) or oral
- Subcutaneous (systemic)
- Typical Dose
- 250 - 500 mcg/day
- 2 - 5 mg twice weekly
- Half-Life
- ~4 hours (stable variant longer)
- ~4-6 hours
- Cycle Length
- 4 - 8 weeks
- 4 - 8 weeks (loading + maintenance)
- Best For
- Tendon, ligament, gut, nerve healing
- Systemic inflammation, muscle injury, cardiac repair
- Oral Bioavailability
- Yes (moderate, for GI targets)
- No
- FDA Status
- Not FDA-approved; research compound
- PubMed Citations
- 100+ studies
- 50+ studies
- Cost (research grade)
- $
- $$